Onconova Therapeutics Inc (NASDAQ:ONTX) major shareholder Tyndall Capital Partners L. P sold 10,927 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $2.83, for a total value of $30,923.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

NASDAQ:ONTX opened at $2.57 on Friday. Onconova Therapeutics Inc has a 1-year low of $1.69 and a 1-year high of $11.17. The firm has a market cap of $15.42 million, a price-to-earnings ratio of -0.52 and a beta of 2.69. The company has a fifty day moving average of $3.20.

Onconova Therapeutics (NASDAQ:ONTX) last released its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.11) by ($0.18). Onconova Therapeutics had a negative net margin of 3,153.42% and a negative return on equity of 310.58%. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.08 million. Sell-side analysts expect that Onconova Therapeutics Inc will post -3.39 EPS for the current fiscal year.

An institutional investor recently bought a new position in Onconova Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in Onconova Therapeutics Inc (NASDAQ:ONTX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 13,086 shares of the biopharmaceutical company’s stock, valued at approximately $28,000. Dimensional Fund Advisors LP owned 0.23% of Onconova Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 38.62% of the company’s stock.

A number of equities analysts recently weighed in on the company. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Maxim Group reiterated a “buy” rating and issued a $16.00 price target on shares of Onconova Therapeutics in a research report on Tuesday, May 14th. HC Wainwright set a $25.00 price target on Onconova Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 14th. Finally, Zacks Investment Research upgraded Hudson Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, May 29th.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.